181 related articles for article (PubMed ID: 18997039)
1. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
[TBL] [Abstract][Full Text] [Related]
3. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.
Ryu SY; Kim MH; Choi SC; Choi CW; Lee KH
J Nucl Med; 2003 Mar; 44(3):347-52. PubMed ID: 12620999
[TBL] [Abstract][Full Text] [Related]
4. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
[TBL] [Abstract][Full Text] [Related]
6. Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma.
Yen RF; Hong RL; Tzen KY; Pan MH; Chen TH
J Nucl Med; 2005 May; 46(5):770-4. PubMed ID: 15872349
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.
Van Laere K; Ceyssens S; Van Calenbergh F; de Groot T; Menten J; Flamen P; Bormans G; Mortelmans L
Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):39-51. PubMed ID: 15309329
[TBL] [Abstract][Full Text] [Related]
8. Defining the priority of using 18F-FDG PET for recurrent cervical cancer.
Yen TC; See LC; Chang TC; Huang KG; Ng KK; Tang SG; Chang YC; Hsueh S; Tsai CS; Hong JH; Lin CT; Chao A; Ma SY; Lin WJ; Fu YK; Fan CC; Lai CH
J Nucl Med; 2004 Oct; 45(10):1632-9. PubMed ID: 15471826
[TBL] [Abstract][Full Text] [Related]
9. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
Kalff V; Duong C; Drummond EG; Matthews JP; Hicks RJ
J Nucl Med; 2006 Jan; 47(1):14-22. PubMed ID: 16391182
[TBL] [Abstract][Full Text] [Related]
10. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival?
Dhull VS; Sharma P; Sharma DN; Maharjan S; Suman Kc S; Patel C; Bal C; Kumar R
Int J Gynecol Cancer; 2014 Feb; 24(2):312-20. PubMed ID: 24407578
[TBL] [Abstract][Full Text] [Related]
12. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
[TBL] [Abstract][Full Text] [Related]
13. (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.
You JJ; Cline KJ; Gu CS; Pritchard KI; Dayes IS; Gulenchyn KY; Inculet RI; Dhesy-Thind SK; Freeman MA; Chan AM; Julian JA; Levine MN
Br J Cancer; 2015 May; 112(11):1737-43. PubMed ID: 25942398
[TBL] [Abstract][Full Text] [Related]
14. The role of PET scanning in the detection of recurrent cervical cancer.
Havrilesky LJ; Wong TZ; Secord AA; Berchuck A; Clarke-Pearson DL; Jones EL
Gynecol Oncol; 2003 Jul; 90(1):186-90. PubMed ID: 12821362
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis.
Goense L; van Rossum PS; Reitsma JB; Lam MG; Meijer GJ; van Vulpen M; Ruurda JP; van Hillegersberg R
J Nucl Med; 2015 Jul; 56(7):995-1002. PubMed ID: 25952733
[TBL] [Abstract][Full Text] [Related]
16. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women.
Unger JB; Ivy JJ; Connor P; Charrier A; Ramaswamy MR; Ampil FL; Monsour RP
Gynecol Oncol; 2004 Jul; 94(1):212-6. PubMed ID: 15262145
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
Sakurai H; Suzuki Y; Nonaka T; Ishikawa H; Shioya M; Kiyohara H; Katoh H; Nakayama Y; Hasegawa M; Nakano T
Gynecol Oncol; 2006 Mar; 100(3):601-7. PubMed ID: 16257440
[TBL] [Abstract][Full Text] [Related]
18. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.
Hicks RJ; Kalff V; MacManus MP; Ware RE; McKenzie AF; Matthews JP; Ball DL
J Nucl Med; 2001 Nov; 42(11):1605-13. PubMed ID: 11696628
[TBL] [Abstract][Full Text] [Related]
19. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
20. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.
Kidd EA; Siegel BA; Dehdashti F; Rader JS; Mutch DG; Powell MA; Grigsby PW
J Clin Oncol; 2010 Apr; 28(12):2108-13. PubMed ID: 20308664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]